Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5310.

https://doi.org/10.1182/blood-2019-125650

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)

Nosha Farhadfar, MD, Ajoy L. Dias, MD, Tao Wang, PhD, Caitrin Fretham, Hemant S. Murthy, MD, Brent R. Logan, Shin Mineishi, MD, Bipin N. Savani, MD, Edward A. Stadtmauer, MD FACP, Saurabh Chhabra, MD, John R. Wingard, MD, Siddhartha Ganguly, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 3256.

https://doi.org/10.1182/blood-2019-125761

Published: 2019

Journal Articles

Impact of Hyperfiltration during Early Childhood on the Natural History of Albuminuria in Pediatric Sickle Cell Anemia

Jeffrey Lebensburger, DO, MSPH, Lee Hilliard, MD, Thomas H. Howard, MD, Inmaculada Aban, PhD, Daniel Feig, MD

Blood (2018) 132 (Supplement 1): 8.

https://doi.org/10.1182/blood-2018-99-115063

Published: 2018

Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2018-99-110976

Published: 2018

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study

Emanuele Angelucci, MD, Junmin Li, Peter L Greenberg, MD, Wu Depei, MD, PhD, Ming Hou, MD, Efreen Montaño Figueroa, PhD, Guadalupe Rodriguez, Xunwei Dong, Jagannath Ghosh, Orna Bornstein, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 234.

https://doi.org/10.1182/blood-2018-99-111134

Published: 2018

Journal Articles

Quantification of Schistocytes from the Peripheral Blood Smear in Thrombotic Thrombocytopenic Purpura (TTP) Compared to Non-TTP Thrombocytopenic Hospitalized Patients

Timothy E. O'Brien, MD, Lynda Bowman, BS, Augustine Hong, Krishna Goparaju, MD BA

Blood (2018) 132 (Supplement 1): 4983.

https://doi.org/10.1182/blood-2018-99-114159

Published: 2018

Journal Articles

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

Blood (2017) 130 (Supplement 1): 817.

https://doi.org/10.1182/blood.V130.Suppl_1.817.817

Published: 2017

Journal Articles

Predictive Value of Gradual Change in Renal Function on Vasculopathy Related Complications and Mortality in Patients with Sickle Cell Disease

Bart J. Biemond, MD PhD, Weel Elsita, Charlotte F.J. Van Tuijn, MPH, Erfan Nur, MD PhD, Liffert Vogt, MDPhD

Blood (2017) 130 (Supplement 1): 986.

https://doi.org/10.1182/blood.V130.Suppl_1.986.986

Published: 2017

Journal Articles

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

Raffaella Origa, Antonio Piga, MD, Immacolata Tartaglione, MD, Giuseppina Della Corte, Ali El-Ali, Jackie Han, Chiara Castiglioni, Gian Luca Forni, MD

Blood (2016) 128 (22): 2466.

https://doi.org/10.1182/blood.V128.22.2466.2466

Published: 2016

Journal Articles

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Elliott Vichinsky, Amal El-Beshlawy, Azzam Alzoebie, Annie Kamdem, MD, Suzanne Koussa, Thirachit Chotsampancharoen, Andreas Bruederle, Jackie Han, Mohsen Elalfy

Blood (2016) 128 (22): 2470.

https://doi.org/10.1182/blood.V128.22.2470.2470

Published: 2016

Journal Articles

Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

Katja Weisel, MD, Meletios A. Dimopoulos, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Antonio Palumbo, MD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Harmut Goldschmidt, MD, Concetta Conticello, MD, Angelo Vacca, MD PhD, Markus Hansson, MD PhD, Neil Miller, CRS, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD, Philippe Moreau, MD

Blood (2014) 124 (21): 4755.

https://doi.org/10.1182/blood.V124.21.4755.4755

Published: 2014

Journal Articles

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Belhoul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Antje Wegener, MD, Dany Habr, MD, Junwu Shen, PhD, Yesim Aydinok, MD

Blood (2013) 122 (21): 1018.

https://doi.org/10.1182/blood.V122.21.1018.1018

Published: 2013

Journal Articles

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

James R. Berenson, MD, Leonard Klein, MD, Robert M. Rifkin, MD, Priti Patel, MD, MS, Sandra Dixon, MS, Ying Ou, PhD, Alan Cartmell, MD

Blood (2013) 122 (21): 1934.

https://doi.org/10.1182/blood.V122.21.1934.1934

Published: 2013

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Victor H Jimenez Zepeda, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP, FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5398.

https://doi.org/10.1182/blood.V122.21.5398.5398

Published: 2013

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Daniel DeAngelo, MD, Wendy Stock, MD, Stephen Petersdorf, MD, Shaw-Ling Wang, Angela Volkert, Erik Vandendries, Anjali Advani, MD

Blood (2012) 120 (21): 2612.

https://doi.org/10.1182/blood.V120.21.2612.2612

Published: 2012

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

The Effect of Vitamin D Supplementation On Calcium Excretion in Thalassemia

Sadana Balachandar, MD, Rachel Randolph, BS, Dorothy A. Kleinert, NP, MPH, CPNP, Sujit Sheth, MD, Patricia Giardina, MD, Maria G Vogiatzi, MD

Blood (2012) 120 (21): 1029.

https://doi.org/10.1182/blood.V120.21.1029.1029

Published: 2012

NARROW

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)

Impact of Hyperfiltration during Early Childhood on the Natural History of Albuminuria in Pediatric Sickle Cell Anemia

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study

Quantification of Schistocytes from the Peripheral Blood Smear in Thrombotic Thrombocytopenic Purpura (TTP) Compared to Non-TTP Thrombocytopenic Hospitalized Patients

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

Predictive Value of Gradual Change in Renal Function on Vasculopathy Related Complications and Mortality in Patients with Sickle Cell Disease

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

The Effect of Vitamin D Supplementation On Calcium Excretion in Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only